Sponsor

Beijing Biostar Pharmaceuticals Co., Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Beijing Biostar Pharmaceuticals Co., Ltd. appears in 10 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials10
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

10 shown
Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast CancerNCT07684456 · lead sponsor · 2026-08-01
NOT_YET_RECRUITING
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain MetastasesNCT06683703 · lead sponsor · 2024-12-01
NOT_YET_RECRUITING
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast CancerNCT05673629 · lead sponsor · 2023-05-30
UNKNOWN
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT05673590 · lead sponsor · 2023-05-12
UNKNOWN
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast CancerNCT05052437 · lead sponsor · 2020-10-15
COMPLETED
Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer(NSCLC)NCT03693547 · lead sponsor · 2019-04-22
COMPLETED
Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast CancerNCT02253459 · lead sponsor · 2014-08-01
COMPLETED
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast CancerNCT05398861 · collaborator · 2022-08-19
RECRUITING
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast CancerNCT05430399 · collaborator · 2022-06-21
RECRUITING
Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast CancerNCT06458413 · collaborator · 2024-06-05
UNKNOWN

Drugs studied in this sponsor's trials

4 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Beijing Biostar Pharmaceuticals Co., Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
capecitabine2
bevacizumab1
docetaxel1
docetaxel Injection1

Sponsor roles

lead sponsor7
collaborator3
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.